Limits...
Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.

Li J, Chen QY, Mo H, Zhang YL, Huang ZF, Zeng YX - Int. J. Biol. Sci. (2011)

Bottom Line: Adoptive immunotherapy with EBV-specific CTLs (EBV-CTL) has been used to treat EBV-associated nasopharyngeal carcinoma (NPC) but only a fraction of the patients shows noticeable clinical response.The patients in Group 2 showed a significant decrease of CD3+CD8+ T-cells, CD3+CD4+ T-cells and CD3+CD45RO+ memory T cells, and increase of CD3⁻CD16+ NK cells compared to Group 1 patients and healthy controls (P<0.001).These findings demonstrate that NPC patients could be distinguished on the basis of their immune status which will affect the efficacy of EBV-CTL immunotherapy.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.

ABSTRACT

Background: Adoptive immunotherapy with EBV-specific CTLs (EBV-CTL) has been used to treat EBV-associated nasopharyngeal carcinoma (NPC) but only a fraction of the patients shows noticeable clinical response.

Patients and methods: Sixty-seven newly diagnosed NPC patients from 2005 to 2007 and 21 healthy donors were collected. Immunological parameters and immune function of PBMCs and EBV-CTL were analyzed by flow cytometer analysis (FACS) and ⁵¹Cr releasing experiment; Molecular characteristics on NPC tumor cells were investigated by immunochemical staining and statistic analysis.

Results: NPC patients can be classified into two groups based on the percentage of CD3+ T cells in peripheral blood before accepted any treatment, (>52.6%, mean-2SE from healthy controls, NPC Group 1; <52.6%, NPC Group 2). The patients in Group 2 showed a significant decrease of CD3+CD8+ T-cells, CD3+CD4+ T-cells and CD3+CD45RO+ memory T cells, and increase of CD3⁻CD16+ NK cells compared to Group 1 patients and healthy controls (P<0.001). EBV-specific T cell responses, were weaker in this group of patients and their tumor cells expressed lower levels of the EBV encoded latent membrane protein (LMP)-1 and HLA class II protein compared with the patients of NPC Group 1 (P<0.05).

Conclusion: These findings demonstrate that NPC patients could be distinguished on the basis of their immune status which will affect the efficacy of EBV-CTL immunotherapy.

Show MeSH

Related in: MedlinePlus

EBV VCA and EA antibody titers and EBV DNA load in the serum from NPC Group 1 and NPC Group 2 patients. Antibody titers (A) to EBV VCA and EA IgA; EBV DNA load (B) in NPC Group 1 and NPC Group 2 patients.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3101529&req=5

Figure 3: EBV VCA and EA antibody titers and EBV DNA load in the serum from NPC Group 1 and NPC Group 2 patients. Antibody titers (A) to EBV VCA and EA IgA; EBV DNA load (B) in NPC Group 1 and NPC Group 2 patients.

Mentions: Furthermore, NPC Group 2 patients showed a significantly higher serum IgA anti EA (P<0.05), and a slightly higher serum IgA anti VCA and serum virus load compared to NPC Group 1 patients (P>0.05, Fig. 3A and 3B). Taken together, these findings suggest that the patients in NPC Group 2 were dysfunction in EBV specific immunity and more difficult to control the EBV infection.


Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.

Li J, Chen QY, Mo H, Zhang YL, Huang ZF, Zeng YX - Int. J. Biol. Sci. (2011)

EBV VCA and EA antibody titers and EBV DNA load in the serum from NPC Group 1 and NPC Group 2 patients. Antibody titers (A) to EBV VCA and EA IgA; EBV DNA load (B) in NPC Group 1 and NPC Group 2 patients.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3101529&req=5

Figure 3: EBV VCA and EA antibody titers and EBV DNA load in the serum from NPC Group 1 and NPC Group 2 patients. Antibody titers (A) to EBV VCA and EA IgA; EBV DNA load (B) in NPC Group 1 and NPC Group 2 patients.
Mentions: Furthermore, NPC Group 2 patients showed a significantly higher serum IgA anti EA (P<0.05), and a slightly higher serum IgA anti VCA and serum virus load compared to NPC Group 1 patients (P>0.05, Fig. 3A and 3B). Taken together, these findings suggest that the patients in NPC Group 2 were dysfunction in EBV specific immunity and more difficult to control the EBV infection.

Bottom Line: Adoptive immunotherapy with EBV-specific CTLs (EBV-CTL) has been used to treat EBV-associated nasopharyngeal carcinoma (NPC) but only a fraction of the patients shows noticeable clinical response.The patients in Group 2 showed a significant decrease of CD3+CD8+ T-cells, CD3+CD4+ T-cells and CD3+CD45RO+ memory T cells, and increase of CD3⁻CD16+ NK cells compared to Group 1 patients and healthy controls (P<0.001).These findings demonstrate that NPC patients could be distinguished on the basis of their immune status which will affect the efficacy of EBV-CTL immunotherapy.

View Article: PubMed Central - PubMed

Affiliation: State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.

ABSTRACT

Background: Adoptive immunotherapy with EBV-specific CTLs (EBV-CTL) has been used to treat EBV-associated nasopharyngeal carcinoma (NPC) but only a fraction of the patients shows noticeable clinical response.

Patients and methods: Sixty-seven newly diagnosed NPC patients from 2005 to 2007 and 21 healthy donors were collected. Immunological parameters and immune function of PBMCs and EBV-CTL were analyzed by flow cytometer analysis (FACS) and ⁵¹Cr releasing experiment; Molecular characteristics on NPC tumor cells were investigated by immunochemical staining and statistic analysis.

Results: NPC patients can be classified into two groups based on the percentage of CD3+ T cells in peripheral blood before accepted any treatment, (>52.6%, mean-2SE from healthy controls, NPC Group 1; <52.6%, NPC Group 2). The patients in Group 2 showed a significant decrease of CD3+CD8+ T-cells, CD3+CD4+ T-cells and CD3+CD45RO+ memory T cells, and increase of CD3⁻CD16+ NK cells compared to Group 1 patients and healthy controls (P<0.001). EBV-specific T cell responses, were weaker in this group of patients and their tumor cells expressed lower levels of the EBV encoded latent membrane protein (LMP)-1 and HLA class II protein compared with the patients of NPC Group 1 (P<0.05).

Conclusion: These findings demonstrate that NPC patients could be distinguished on the basis of their immune status which will affect the efficacy of EBV-CTL immunotherapy.

Show MeSH
Related in: MedlinePlus